دورية أكاديمية
أعرض في EDS

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes.

التفاصيل البيبلوغرافية
العنوان: Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes.
المؤلفون: Ramos GS; Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Vallejos VMR; Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Borges GSM; Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Almeida RM; Department of Parasitology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Alves IM; Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Aguiar MMG; Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Fernandes C; Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Guimarães PPG; Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Fujiwara RT; Department of Parasitology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Loiseau PM; Faculty of Pharmacy, Antiparasite Chemotherapy, UMR 8076 CNRS BioCIS, University Paris-Saclay, F-92296 Chatenay-Malabry, France., Ferreira LAM; Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Frézard F; Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
المصدر: Pharmaceutics [Pharmaceutics] 2022 May 05; Vol. 14 (5). Date of Electronic Publication: 2022 May 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Liposomal amphotericin B (AmB) or AmBisome ® is the most effective and safe therapeutic agent for visceral leishmaniasis (VL), but its clinical efficacy is limited in cutaneous leishmaniasis (CL) and HIV/VL co-infection. The aim of this work was to develop a formulation of AmB in PEGylated liposomes and compare its efficacy to AmBisome ® in a murine model of CL. Formulations of AmB in conventional and PEGylated liposomes were characterized for particle size and morphology, drug encapsulation efficiency and aggregation state. Those were compared to AmBisome ® in Leishmania amazonensis -infected BALB/c mice for their effects on the lesion size growth and parasite load. The conventional and PEGylated formulations showed vesicles with 100-130 nm diameter and low polydispersity, incorporating more than 95% of AmB under the non-aggregated form. Following parenteral administration in the murine model of CL, the PEGylated formulation of AmB significantly reduced the lesion size growth and parasite load, in comparison to control groups, in contrast to conventional liposomal AmB. The PEGylated formulation of AmB was also effective when given by oral route on a 2-day regimen. This work reports for the first time that PEGylated liposomal AmB can improve the treatment of experimental cutaneous leishmaniasis by both parenteral and oral routes.
References: J Drug Target. 2018 Apr;26(4):357-364. (PMID: 29041824)
Clin Infect Dis. 2015 Sep 15;61(6):945-9. (PMID: 26048961)
Antimicrob Agents Chemother. 2017 Aug 24;61(9):. (PMID: 28630182)
Br J Dermatol. 2020 Aug;183(2):389-391. (PMID: 32078162)
Expert Opin Drug Deliv. 2019 Oct;16(10):1063-1079. (PMID: 31433678)
Eur J Pharm Sci. 2015 Apr 5;70:125-31. (PMID: 25660615)
Int J Parasitol Drugs Drug Resist. 2018 Aug;8(2):223-228. (PMID: 29673889)
J Infect Dis. 2012 Jan 15;205(2):333-6. (PMID: 22158723)
Artif Cells Nanomed Biotechnol. 2018;46(sup1):521-531. (PMID: 29385910)
Biochim Biophys Acta. 1992 Aug 14;1113(2):171-99. (PMID: 1510996)
Mol Pharm. 2015 Feb 2;12(2):420-31. (PMID: 25558881)
Pharmaceutics. 2021 Feb 19;13(2):. (PMID: 33669803)
Pharmaceutics. 2019 Feb 26;11(3):. (PMID: 30813569)
J Antibiot (Tokyo). 2011 Nov;64(11):735-9. (PMID: 21971300)
Biophys Chem. 1999 Mar 8;77(1):69-77. (PMID: 17027469)
J Immunol Res. 2019 Jan 10;2019:4103819. (PMID: 30756088)
Clin Infect Dis. 2016 Dec 15;63(12):1539-1557. (PMID: 27941143)
J Infect Dis. 2009 Aug 1;200(3):357-60. (PMID: 19545212)
Antimicrob Agents Chemother. 2020 Jun 23;64(7):. (PMID: 32284386)
Parasitol Res. 2019 Oct;118(10):3077-3084. (PMID: 31401656)
Antimicrob Agents Chemother. 2018 Feb 23;62(3):. (PMID: 29263075)
Med Mycol. 2016 Mar;54(3):223-31. (PMID: 26768369)
PLoS Negl Trop Dis. 2017 Nov 20;11(11):e0006094. (PMID: 29155816)
N Engl J Med. 2010 Feb 11;362(6):504-12. (PMID: 20147716)
Expert Opin Drug Deliv. 2014 Oct;11(10):1551-60. (PMID: 24962630)
Int J Nanomedicine. 2015 Dec 02;10:7265-74. (PMID: 26664117)
Pathogens. 2021 Sep 28;10(10):. (PMID: 34684202)
PLoS Negl Trop Dis. 2010 Dec 07;4(12):e913. (PMID: 21151883)
معلومات مُعتمدة: 425332/2018-7, 305659/2017-0, 306198/2021-5, 401390/2020-9 National Council for Scientific and Technological Development
فهرسة مساهمة: Keywords: PEGylation; amphotericin B; cutaneous leishmaniasis; leishmaniasis; liposomes; oral route
تواريخ الأحداث: Date Created: 20220528 Latest Revision: 20220716
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9147047
DOI: 10.3390/pharmaceutics14050989
PMID: 35631575
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4923
DOI:10.3390/pharmaceutics14050989